In major orthopaedic surgery, it is recommended to detect and correct preoperative anaemia several weeks prior to surgery. However, in many cases, the procedure is urgent or the patient is evaluated shortly before the intervention. As iron deficiency is the leading cause of perioperative anaemia, an exhaustive review of the literature was performed to assess the efficacy and safety of short-term perioperative intravenous, with or without erythropoietin, or postoperative oral or intravenous supplementation in major orthopaedic surgery. Overall, 20 studies met the inclusion criteria. There were 13 randomized trials (moderate quality) and seven observational studies (low to very low quality). The primary outcomes were reduction in transfusion requirements, haemoglobin increase and medication side-effects during the study period. Data analysis showed that postoperative oral iron administration neither increased haemoglobin nor reduced transfusion requirements, and it was associated with significant gastrointestinal adverse effects (15%). In contrast, for some patient populations, perioperative or postoperative administration of intravenous iron, with or without recombinant erythropoietin, may reduce transfusion requirements and/or hasten the recovery from postoperative, with few clinically relevant adverse effects (<2%). However, discrepancies between randomized trials and observational studies on the possible beneficial effects of short-term perioperative intravenous iron administration were found for patients undergoing surgery for hip fracture repair. Further studies are needed to elucidate when the treatment should be started, which combination of drugs should be used, and which patient groups would be most benefit.
Introduction
Patients undergoing major orthopaedic surgery (MOS) procedures may be exposed to the effects of anaemia, blood loss and allogeneic blood transfusion (ABT) that may adversely influence in their postoperative outcome [1] . Preoperative anaemia is an independent risk factor for increased risk of postoperative complications and hospital or 30-day mortality [2] .
In a systematic review of MOS patients, preoperative anaemia was highly prevalent both in total hip or knee arthroplasty (24%) and in hip fracture repair surgery (44%) [3] . Postoperative anaemia was even more common (51% and 87%, respectively) [3] . In our area, a recent observational study (3342 patients), the overall prevalence of preoperative anaemia (haemoglobin [Hb] <13 g/dl) was 36% in elective procedures, being 26% in MOS [4] .
A preoperative Hb level <13 g/dl is the most important independent risk factor for transfusion in MOS procedures with moderate-to-severe bleeding [5] . Since intra-operative or postoperative anaemia develops acutely, ABT continues to be the method most frequently used to quickly and effectively restore the Hb levels, especially in non-elective surgery [5] . However, there are a number of reasons for reducing the use of the ABT, including high processing and administration costs and risks of adverse effects.
All this has promoted the development of multidisciplinary and multi-modal programmes for the comprehensive management of MOS patients, generically known as patient blood management (PBM) programmes, to reduce or eliminate the need for ABT and improve the clinical outcome [1, 6] . Perioperative anaemia management constitutes a fundamental pillar of PBM programmes in MOS.
The presence of preoperative anaemia should be investigated, at least 30 days before the intervention, in order to its classification and treatment [5] . In the postoperative period, anaemia detection should be early detected and treated to avoid or reduce ABT requirements and hasten functional recovery [6] . Absolute or functional iron deficiency is the leading cause of anaemia in MOS [4, 7] , and the National Institute for Health and Care Excellence (NICE) in the UK recommends offering oral or intravenous (IV) iron before or after surgery to patients with iron deficiency anaemia [5] .
However, often this time frame for anaemia management is not available, either because it is non-elective procedure (e.g. hip fracture repair) or because the patient is evaluated shortly before the intervention. Even in these cases, any available time should be used to initiate anaemia treatment, which ultimately can be started in the postoperative period [2, 8] . In this regard, we performed an exhaustive literature review to ascertain the efficacy and safety of short-term perioperative administration of oral or intravenous iron, with or without recombinant human erythropoietin (EPO), for anaemia management in MOS patients.
Methods

Search strategy
A search on MEDLINE (via PubMed) was performed using multiple key words (e.g. iron OR intravenous iron OR erythropoietin AND orthopaedic surgery OR subcapital fracture OR femoral neck fracture OR intertrochanteric fracture OR subtrochanteric fracture OR knee surgery OR hip surgery OR arthroplasty OR spine surgery), in different sequences, to ensure the inclusion of all potential studies, published between 1976 and 2018.
Inclusion criteria
Studies were included if they fulfilled the following criteria: (1) study population was adults undergoing elective or non-elective MOS; (2) the intervention consisted of short-term perioperative administration of IV iron (≤7 days before and/or after surgery), with or without EPO, or postoperative administration of oral iron (Fig. 1) ; (3) randomized controlled trials (RCTs), or observational prospective or retrospective studies; (4) articles should be written in Spanish or English. Two authors (SGR and MAMR) independently assessed the articles for compliance with the inclusion criteria. Any disagreement was resolved through discussion or consultation with a third independent investigator (MM).
-6
-5 -4 -3 -2 -1 +1 +2 +3 +4 +5 +6 +7 +8
Weeks
Surgery
IV iron
Oral iron
Preoperative Postoperative
Oral or IV iron
Short-term perioperative
Weeks Fig. 1 Iron supplementation modalities according to the time of initiation. In major orthopaedic surgery, preoperative iron administration (4-6 weeks prior to surgery) is the standard approach for treating iron-deficient patient iron recommended by most guidelines [2, 5, 6, [36] [37] [38] . Short-term perioperative intravenous iron administration (up to 1 week before and/or after surgery) has been also suggested by some guidelines [2, 37] . Postoperative intravenous iron administration is usually restricted to hospital stay (approximately 1 week), whereas postoperative oral iron supplementation is usually prescribed for 4-8 weeks [5, 8] .
Data extraction
From each of the included studies, the following set of data was extracted, if available: author and year of publication, type of study (RCT, observational), type of surgery, groups of patients, type, dose, initiation and duration of iron treatment, doses of EPO, Hb at baseline, final Hb and Hb increment (reported or calculated), transfusion rate (%) and index (units/patient), infection and mortality rates, length of hospital stay, and treatmentrelated adverse events. Regarding the latter, particular attention was paid to gastrointestinal adverse effects of oral iron (e.g. nausea, vomiting, epigastric ache, flatulence, diarrhoea or constipation) and to hypersensitivity reactions to intravenous iron (e.g. hypotension, anaphylaxis).
Data synthesis
Study data were grouped into tables according to the type of study (RCT, observational), type of iron supplementation (oral or intravenous), time of treatment in relation to the surgical procedure (perioperative, between 7 days before and 7 days after the surgery, or postoperative, only after surgery) and type of surgery (elective or nonelective). The primary outcomes were Hb increase, reduction in transfusion requirements and medication sideeffects during the perioperative period. The secondary outcomes were the length of hospital stay, rate of postoperative infection and mortality. Due to the great variability in composition, dosage and duration of treatments in the reviewed studies, as well as in the use of other transfusion alternatives (e.g. tranexamic acid, postoperative cell salvage) or in transfusion protocols, a meta-analysis of data was not performed. However, differences in Hb increments (minimum, maximum) and reduction of transfusion rates (relative risk [RR] and 95% confidence interval [95% CI]) were estimated, when possible (EPIDAT 3Á1 software, licensed to Conselleria de Sanidade, Xunta de Galicia, Spain).
Results
Search results and included studies
The initial search yielded a total of 267 items. After the review of study summaries, 243 failed to meet the inclusion criteria and were excluded. The full text of the 24 remaining articles was retrieved for a detailed assessment. Of these, four hip fracture studies were subsequently excluded [9-12], as they had been included in a pooled analysis together with new data [13] . Therefore, 20 studies were considered appropriate for inclusion in this review: nine with perioperative intravenous iron, six with postoperative oral iron and five with postoperative intravenous iron [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] (Tables 1-4) . The overall quality of the evidence provided by the RCT was moderate, and that provided by observational studies was considered low or very low.
Efficacy
Perioperative intravenous iron in elective MOS
The efficacy of perioperative intravenous iron administration of (iron sucrose or iron isomaltoside) to reduce transfusion rates in knee or hip arthroplasty has been evaluated in one RCT and three observational studies (3574 patients) [14-17] ( Table 1) .
A RCT in anaemic patients undergoing bilateral knee arthroplasty found that iron sucrose (up to three 200 mg doses) plus EPO (3000 IU) decreased ABT rate with respect to placebo (20% vs. 54%, respectively; relative risk [RR]: 0Á38, 95% confidence interval [CI]: 0Á21-0Á68: P = 0Á0006) [15] . In addition, at postoperative week 6, treated patients showed higher Hb values (12Á7 g/dl vs. 11Á8 g/dl, respectively; P < 0Á05) [15] . Data on postoperative infection, mortality or length of stay were not reported.
In a series of unilateral knee arthroplasty patients (n = 139), Cuenca et al. [15] showed that administration of two 200 mg doses of iron sucrose (48 h before and 48 h after surgery), with or without EPO (1 9 40 000 IU; 48 h before surgery if Hb <13 g/dl) resulted in a very low ABT rate (2Á9%). In a subsequent series of unilateral knee arthroplasty patients (n = 173), the addition of postoperative autologous blood salvage to this pharmacological treatment did not improve the ABT rate (5Á2%) or postoperative Hb levels, but decreased the length of hospital stay (8 vs. 10 days, respectively; P < 0Á05). There were no differences in postoperative infection rates (2Á1% vs. 2Á3%; P = 1Á000). At the authors' institution, previous ABT rate in unilateral knee arthroplasty was 30% [33] .
In case series of bilateral knee arthroplasty, Suh et al. [16] observed that the combined use of perioperative intravenous iron isomaltoside (1000 mg) and topical tranexamic acid (2 g) virtually eliminates ABT requirements (1Á3%). Data on postoperative infection, mortality or length of stay were not reported.
More recently, in a large retrospective study, Zhang et al. [17] showed that intravenous (20 mg/kg) plus topical (1 g) tranexamic acid administration resulted in very low ABT in hip or knee arthroplasty. Additional perioperative administration of intravenous iron sucrose (200 mg/ 48 h) and EPO (10 000 IU/day) to anaemic patients, rather than oral iron (150-300 mg/day), further reduced ABT in hip arthroplasty (3Á9% vs. 7Á2%; RR: 0Á54, 95% ?, Not specifically reported; EPO, recombinant human erythropoietin; Hb, haemoglobin; IIM, iron isomaltoside; IS, iron sucrose; PDR, postoperative drain reinfusion; RCT, randomized controlled trial; SC, standard care; THA, total hip arthroplasty; TKA, total knee arthroplasty. CI: 0Á35-0Á82, P = 0Á0035,) but not in knee arthroplasty (2Á2% vs. 2Á9%; RR: 0Á74. 95% CI: 0Á37-1Á49, P = 0Á4876, for knee arthroplasty), and shortened hospital stay by more than 1 day (P < 0Á001) ( Table 1 ). There were no differences in postoperative infection rates (0Á7% vs. 0Á7%; P = 0Á941).
Perioperative intravenous iron in non-elective MOS
In hip fracture repair surgery, five studies (three RCTs, two observational; 2063 patients) have evaluated the effect of perioperative intravenous iron administration (iron sucrose or ferric carboxymaltose), with or without EPO, on transfusion requirements, with varying results [13, 18-21] ( Table 2 ).
Compared to standard care, in one RCT, perioperative intravenous iron administration did not result in a reduction in overall transfusion requirements (33% vs. 41%; RR: 0Á80, 95% CI: 0Á55-1Á17, P = 0Á3179), though it halved postoperative ABT rate (10% vs. 21%; RR: 0Á49, 95% CI: 0Á24-0Á99, P = 0Á048) [18] . In subgroup analysis, a significant reduction of ABT rates was also observed for patients with subcapital fracture (14Á3% vs. 45Á7%, P = 0Á004) or admission Hb <12 g/dl (18Á3% vs. 36%, P = 0Á049) [18] . A second RCT demonstrated that combined administration of intravenous iron and EPO was more efficacious than intravenous iron monotherapy for reducing postoperative transfusion requirements (1Á5 U/ patient vs. 2Á5 U/patient, P = 0Á034) and improving Hb at postoperative day 7 (10Á1 g/dl vs. 9Á1 g/dl; P = 0Á015) [19] . Conversely, in a third RCT that only included patients with Hb <12 g/dl, treatment with intravenous iron, with or without EPO, did not reduce transfusion rates in relation to placebo (52%, 52%, 54%, respectively). However, compared to placebo, the group receiving intravenous iron and EPO showed higher Hb levels at discharge (10Á3 g/dl vs. 9Á7 g/dl, respectively; P = 0Á009) and 60 days after the intervention (12Á5 g/dl vs. 11Á9 g/ dl, respectively; P = 0Á05), with fewer patients being anaemic 60 days after discharge (52% vs. 39%, respectively; P = 0Á015), though there were no differences in quality of life scores [20] .
However, there were differences between RCTs regarding mean time to surgery from hospital admission ( Table 2 ) and transfusion protocols that might have influenced the results. Thus, patients may receive a RBC transfusion when: (1) postoperative Hb <8 g/dl or <9 g/ dl in patients with a history of cardiorespiratory conditions, or any Hb in patients with symptoms of untreated anaemia [18]; (2) postoperative Hb <9 g/dl or any discomfort or pathologic signs from cardiovascular, central nervous or renal system related to anaemia [19] ; or (3) postoperative Hb <7 g/dl independently of symptoms (3 RBC units) or postoperative Hb 7Á1-8Á9 g/dl plus severe symptoms and/or cardiovascular risk factors (2 RBC units) [20] .
None of the three RCTs reported an increased risk of infection or mortality or a prolongation of hospital stay (Table 2) .
In contrast, compared to no iron, in two observational studies using a similar transfusion threshold (Hb <8 g/dl or <9 g/dl if anaemia symptoms and/or cardiovascular risk factors), perioperative administration of iron sucrose (up to 600 mg), with or without one EPO dose (40 000 IU), resulted in a significant reduction in both the percentage of patients requiring transfusion (32% vs. 49Á5%, respectively; RR: 0Á64, 95% CI: 0Á57-0Á74, P < 0Á0001) and the number of transfused units, which was accompanied by a reduction in length of hospital stay and/or lower infection and 30-day mortality rates [13, 21] ( Table 2) . Ongoing RCTs will hopefully help to solve out these discrepancies (EudraCT Number: 2014-001923-53; EudraCT Number: 2011-003233-34, ClinicalTrials.gov Identifier: NCT01084122, ISRCTN76424792).
Postoperative oral iron in elective and non-elective MOS
The efficacy of the postoperative administration of oral iron (ferrous sulphate) to improve the Hb levels has been evaluated in six RCTs of patients undergoing elective knee or hip arthroplasties (four RCTs, n = 317) or hip fracture repair (two RCTs, n = 366), without preoperative iron deficiency or anaemia [22] [23] [24] [25] [26] [27] (Table 3) . Elemental iron doses ranged between 130 and 420 mg/day, and iron supplementation was maintained between 2 and 10 weeks. At the end of treatment period, the differences in Hb increments between patients receiving oral iron and those receiving no iron or placebo were small and heterogeneous (Table 3 ). These differences were only significant in two studies: one in knee or hip arthroplasty (0Á75 g/dl; 95% CI: -0Á02 to 1Á52) [25] and one in hip fracture repair (0Á76 g/dl; 95% CI: 0Á01-1Á51) [34] . Most reviewed studies did not provide information on transfusion requirements, postoperative complications, mortality or length of hospital stay.
Postoperative intravenous iron in elective MOS
The efficacy of the postoperative intravenous iron administration (iron sucrose or ferric carboxymaltose) to improve Hb levels has been evaluated in five studies including 1008 anaemic patients, mostly undergoing elective MOS (three RCTs, two observational) [28] [29] [30] [31] [32] (Table 4) . Pooled data from the three RTCs showed that, compared to control (oral iron, no iron or placebo), postoperative intravenous iron did not reduce the ABT rate (4Á6% vs. 6Á5%, respectively; RR: 0Á71, 95% CI: 0Á29-1Á72, P = 0Á4869) or the number of transfused units [28] [29] [30] . However, in the most recent RCT, highdose ferric carboxymaltose led to a significant reduction in ABT and infections rates, as well as in the length of hospital stay [30] (Table 4) . Similarly, in two large pairmatched observational studies (664 patients), postoperative intravenous iron reduced the ABT rate (27Á4% vs. 43Á4%; RR: 0Á43, 95% CI: 0Á51-0Á78, P < 0Á0001), number of transfused units and length of hospital stay, without affecting postoperative infection or mortality rates [31, 32] (Table 4) .
Regarding postoperative anaemia improvement, highdose intravenous iron supplementation (%1000 mg/patient; two RCTs, one observational) resulted in a higher Hb increment at 4-6 postoperative weeks with respect to standard care or oral iron (0Á5, 0Á8 and 1Á6 g/dl, respectively) [29, 30, 32] (Table 4 ). In the RCT by Bisbe et al. [29] , there was only a trend to higher Hb increment in the intravenous iron group compared with the oral iron group (+0Á5 g/dl, P = 0Á075), but fewer patients form the intravenous iron group received preoperative anaemia treatment, intra-operative tranexamic acid and/or postoperative shed blood reinfusion (60% vs. 79%, respectively; RR: 0Á76, 95% CI: 0Á60-0Á97, P = 0Á03) [29] . However, the differences in Hb increments were significant when the analysis was restricted to patients with preoperative iron deficiency (+0Á7 g/dl, P = 0Á03), postoperative Hb <10 g/dl (+1Á3 g/dl, P = 0Á018) or both (+1Á5 g/dl, P = 0Á0Á17) [29] . Additionally, in the two RCTs, high-dose postoperative intravenous iron supplementation resulted in better scores for physical activity-related quality of life [29, 30] . In contrast, no significant differences in postoperative Hb increments were observed in studies using lower intravenous iron doses (600 mg) [28, 31] .
Safety
Four out of 14 studies involving intravenous iron administration did not specifically report on the adverse drug effects (ADEs) [14-17, 21]. In the remaining 10 studies (2200 patients), only 25 ADEs were reported, mostly occurring in hip fracture patients (23). Thus, the overall incidence of ADEs with intravenous iron, with or without EPO, was 1Á13%. Of these 25 ADEs, 13 were gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or constipation) [19, 20] Globally, there was no difference the incidence of clinically relevant ADEs in patients receiving intravenous iron, with or without EPO, compared to those assigned to control (placebo, oral iron, no iron; 1063 patients, 9 ADEs) (1Á13% vs. 0Á85%; RR: 1Á34, 95% CI: 0Á63-2Á86, P = 0Á5620). The small total number of reported ADEs precludes for a separate analysis according to the iron formulation used.
In contrast, in the RCTs evaluating the efficacy of postoperative oral iron, patients receiving iron supplementation were more likely to complain of major gastrointestinal adverse effects, compared to those receiving no iron or placebo (16Á4% vs. 4Á8%; RR: 3Á43, 95% CI: 1Á96-5Á96, P < 0Á001).
Discussion
We performed an exhaustive review of the efficacy and safety of short-term perioperative iron administration in MOS patients. Data analysis showed that postoperative oral iron administration neither increased haemoglobin nor reduced transfusion requirements, and it was associated with significant gastrointestinal adverse effects (Table 3 ). In contrast, perioperative or postoperative administration of intravenous iron, with or without EPO, might decrease transfusion requirements and hasten the recovery from postoperative anaemia, at least in some patient subgroups, without clinically relevant adverse effects. However, data from RCTs and observational studies were sometimes contradictory, especially in hip fracture patients (Table 2) .
In MOS patients, preoperative anaemia is prevalent and in itself a modifiable risk factor for allogeneic transfusion and poor postoperative outcome [3] . Postoperative anaemia is still more prevalent, influencing clinical outcome, functional recovery and quality of life [3] . Therefore, perioperative anaemia management is a fundamental pillar of PBM programmes [2, 5, 6, 8] .
In elective MOS, detection and classification of preoperative anaemia should be done as soon as possible (4-6 weeks prior to surgery) to allow appropriate treatment. Whenever feasible, it must be corrected before an elective MOS procedure, which can lead to surgery rescheduling. On the other hand, it is possible to treat pharmacologically most cases of moderate anaemia, whereas transfusion should be reserved for patients with severe symptomatic anaemia, active bleeding or haemodynamic instability [2, 5, 6, 8] . Various clinical guidelines have analysed the efficacy and safety of the pharmacological options for treating anaemia and issued recommendations on their use [2, 5, 6, 8, [35] [36] [37] [38] . In addition, within the context of a PBM programme, treatment of preoperative anaemia has been proved highly cost-effective [39, 40] .
Should the recommended time frame not be available, any available time should be used to, at least, detect and classified anaemia, and start treatment; ultimately, this may be continued/initiated postoperativel [2, 8, 37, 38] . Several algorithms for management of preoperative anaemia and postoperative anaemia have been published [2, 8, 36] . Since iron deficiency, either absolute (iron deficiency anaemia) or functional (anaemia of inflammation, also referred to as anaemia of chronic disease), is very prevalent among MOS patients [4, 7] , we reviewed the efficacy and safety of short-term perioperative iron administration in this clinical setting.
Twenty studies were considered appropriate for inclusion in this review (13 RCTs, 7 observational) [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . At the individual level, the risks of bias limited the overall quality of the evidence provided by the RCT (moderate quality), and observational studies (low or very low quality). In addition, there were clinical heterogeneity and methodological heterogeneity between different studies affecting iron formulations, dosages and duration of iron treatment, duration of follow-up, comparison groups, blinding level of patients and researchers, use of other blood savings strategies and transfusion protocols, which make difficult to draw definitive conclusions.
Efficacy
With the limitation imposed by the quality of the evidence, the analysis of included studies suggests that perioperative or postoperative intravenous iron administration, with or without EPO, can improve Hb levels and reduce transfusion requirements and length of hospital stay, without increasing the postoperative morbidity and mortality, at least in some patient subgroups (Tables 1, 2 
and 4).
Major discrepancies between RCTs and observational studies on the possible beneficial effects of short-term intravenous iron administration were found in patients undergoing surgery for hip fracture repair. Differences in patient selection, mean time to surgery from hospital admission, intravenous iron doses and administration schedule, and transfusion protocols might have play a role ( Table 2 ). For instance, in the multicentre, doubleblinded RCT by Bernabeu-Vittel et al.
[20] inclusion criteria and transfusion protocol might have been misleading. They included 306 anaemic hip fracture patients (Hb 9-12 g/dl). First, virtually, all hip fracture patients with preoperative Hb <10 g/dl will be transfused perioperatively due to a further Hb decrease induced by perioperative blood loss; thus, a blood-saving effect of intravenous iron, with or without EPO, should not been expected. Second, a previous RCT in hip fracture repair showed a benefit of intravenous iron for those with Hb >12 g/dl [18] , and in Europe, EPO administration is approved for orthopaedic surgery with baseline Hb 10-13 g/dl. Third, available data suggest that an Hb <13 g/dl should be considered as suboptimal in surgical settings in which significant blood loss is expected [2] . Thus, the authors may have included patients who most probably will not benefit from treatment while excluded others who may benefit from it. In fact, previously published transfusion data from patients with hip fracture receiving intravenous iron, with or without EPO, were stratified according to admission Hb (9-13 g/dl; n = 582) [13, 41] . Data analysis showed that for Hb 9-12 g/dl, there were no differences in ABT rates regardless treatment. However, for those presenting with Hb between 12 and 13 g/dl, which represent one-third of study sample, treatment with intravenous iron, with or without EPO, led to a significant reduction of ABT rate compared to standard care (oral iron or no iron) [41] . On the other hand, their transfusion protocol dictates that patients with Hb <7 g/dl will receive 3 RBC units, independently of symptoms, and those with Hb 7Á1-8Á9 g/dl and severe symptoms will receive 2 RBC units [20] . According to guidelines from most scientific societies and consensus statements, in non-bleeding patients, RBC should be transfused one unit at the time, followed by patient reassessment for additional transfusion requirements [5, 6, 8, 38] . A fixed amount of PRC units to be transfused is not acceptable and makes difficult to observe any benefit of the erythropoiesis-stimulating therapy on transfusion requirements.
As for postoperative oral iron, available data from RCT showed that, when compared to no iron or placebo, high doses of ferrous sulphate (100-300 mg elemental iron per day) did not hasten the recovery from postoperative anaemia following lower limb arthroplasty [22] [23] [24] [25] or hip fracture repair [26, 27] (Table 3) . Consequently, most authors considered that administration of iron supplements after elective total hip or total knee arthroplasty or hip fracture repair did not appear to be worthwhile. However, the vast majority of these studies did not include patients with preoperative anaemia and/or iron deficiency or confirmed postoperative iron deficiency; that is, those who potentially could benefit the most from iron supplementation. This led to heterogeneity between studies regarding the effect of postoperative oral iron on Hb levels and should be considered as another study limitation (Table 3) .
Nevertheless, even in the presence of iron deficiency, it is unlikely that postoperative administration of oral iron salts was effective in correcting anaemia since the high levels of hepcidin, induced by surgery-associated inflammation, would inhibit its intestinal absorption [42] . In this regard, the results of the IRONOUT study in patients with chronic heart failure and iron deficiency seem to support the ineffectiveness of oral iron salts in the setting of inflammation [43] . On the other hand, low dose (30-60 mg) oral sucrosomial iron has been proven effective for treating anaemia in clinical settings (e.g. chronic kidney disease, bariatric surgery) where intravenous iron seemed to be the only treatment option [44] [45] [46] . Unfortunately, the possible role of this newer oral iron formulation in surgical patients has not been yet studied.
In contrast, high-dose postoperative intravenous iron supplementation resulted in a higher Hb increment at 4-6 postoperative weeks with respect to standard care or oral iron ( Table 4 ). The reason that high-dose intravenous iron works in this context might be related to its ability for upregulating macrophage ferroportin [47] . Intravenous iron formulations are taken up by macrophages and degraded, leading to a transient, dose-dependent increase in intracellular labile iron, before being stored as ferritin. Intracellular iron increases ferroportin expression via upregulation of intracellular iron regulatory proteins I and II, partly overcoming hepcidin blockade and allowing iron export to plasma, where it loads transferrin and is transported to the bone marrow for erythropoiesis [48] .
Quality of life
Only three studies have evaluated the effect of postoperative treatment with iron by means of EQ-5d or SF-36 surveys [20, 29, 30] . In knee arthroplasty, Bisbe et al. [29] . found that treatment with ferric carboxymaltose was associated with better results in the EQ-5d subscales of 'regular activities' or 'anxiety/depression' 30 days after the intervention. The study by Khalfallah et al. [30] . showed a significant difference in the SF-36 subscale of 'physical role' (problems in performing working or other daily activities due to physical health) in favour of the intravenous iron group at 4 and 12 postoperative weeks. In contrast, in hip fracture repair surgery, Bernabeu-Wittel et al. [20] . found no differences in quality of life, as assessed with SF-36v2, between patients receiving intravenous iron, with or without EPO, or placebo. Additionally, none of the revised works collected data on joint functionality after knee or hip arthroplasty or investigated whether the improvement in Hb levels allowed an earlier rehabilitation, which can be considered another limitation of these studies.
Safety
The risks of hypersensitivity reactions, oxidative stress or infection are common concerns with intravenous iron. Three different IV iron products were used in the analysed studies: ferric carboxymaltose, iron isomaltoside and iron sucrose. The European Medicines Agency (EMA) argues that, when appropriately indicated and administered, their benefits outweigh the risks, the incidence of severe allergic reactions is low, and there are no differences in the security profile of available intravenous iron formulations [49] .
Minor infusion reactions occur in approximately 1 in 100 intravenous iron administrations and are due to labile free iron and not to hypersensitivity [50] . They are characterized by chest and back pressure, flushing, itching and/or urticaria, but without accompanying hypotension, tachypnoea, tachycardia, wheezing, and stridor or periorbital oedema. Usually, minor infusion reactions are mild and abate spontaneously within a 5-10 min, without any intervention and rarely recur with rechallenge at lower infusion rate [51] . Self-limited hypotension during intravenous iron infusion could be considered hypersensitivity or vascular reactions to free iron, and low rates have been reported for ferric carboxymaltose (1Á04%), iron isomaltoside (0Á34%) and iron sucrose (0Á33%) [52] [53] [54] . In contrast, the overwhelming majority of severe and potentially lethal reactions were due to high molecular weight iron dextran formulations, which are no longer available [55] . When high molecular weight iron dextran is excluded, intravenous iron is associated with an estimated severe adverse effects incidence of <1 in 250 000 administrations [56] . As for short-term intravenous iron administration, no tissue damage due to oxidative stress by labile iron could be expected [57, 58] . In fact, a recent study showed that 1000-2000 mg preoperative intravenous iron therapy does not have a profound effect on long-term overall and disease-free survival in anaemic colorectal cancer patients [59] .
The analysed studies did not show an increased risk of infection or mortality among patients who received intravenous iron, whereas less than 2% experienced clinically significant adverse reactions (Tables 1, 2 and 4) . This is consistent with the results from a previous review [60] and a recent meta-analysis of 103 EACs (1965-2013) on the use of intravenous iron in various indications [61] . In contrast, over 15% of patients who received postoperative oral iron reported major gastrointestinal adverse effects (Table 3) , which in some cases led to treatment discontinuation, although this percentage is lower than that observed in other clinical scenarios [62] .
With respect to EPO administration in MOS, a recent meta-analysis confirmed its efficacy to reduce ABT rate, with no difference in the risk of thromboembolism compared to placebo [63] . However, the authors pointed out that the majority of patients received thromboprophylaxis and had low cardiovascular and thromboembolic risk. In addition, they recommended that the decision to use EPO on a routine base should be balanced against its costs, which may be relatively high. It is important to highlight that intravenous iron administration neither exerts a direct influence on erythropoiesis nor leads to supraphysiologic Hb levels (as it may occur with the EPO) and, therefore, does not increase the risk of thromboembolic events. Moreover, it could even reduce thromboembolic events by decreasing iron deficiency-induced thrombocytosis [64] .
Conclusions
Clinical practice guidelines recommend the detection and classification of preoperative anaemia at least 4 weeks prior to MOS [2, 6, [36] [37] [38] . However, there are numerous barriers that hinder the implementation of this recommendation in elective MOS [65, 66] , whereas it does not apply to non-elective MOS. Should this time frame not be available, published studies suggest a benefit from shortterm perioperative treatment with intravenous iron, with or without EPO, at least for some patient populations. However, more studies are needed to elucidate when it should be started, which combination of drugs should be used, and which patient groups would benefit most. In addition, further studies assessing the effect on functional recovery and quality of life, and the cost-effectiveness of these therapeutic interventions are also warranted.
